What AI biotech form is backed by Bill Gates and the shares are worth around $25.

**Bill Gates' Investment in AI Biotech**:
1. **Foundation Capital**: Bill Gates has invested in AI-driven pharmaceutical companies through his foundation, the Bill and Melinda Gates Foundation. He has shown a particular interest in biotechnology, with a significant portion of the foundation's portfolio dedicated to this sector.
2. **Top Holdings**: The top three biotech stocks held by the foundation account for 79% of its portfolio, with BioNTech (BNTX), Vir Biotechnology (VIR), and Immunocore (IMCR) being the key holdings. These companies are at the forefront of developing innovative treatments and technologies in the biotech space.
3. **Investment Strategy**: Gates has been actively involved in supporting AI-driven drug discovery and development, as evidenced by his investment in Exscientia, a company focused on AI-driven drug design. This strategic approach highlights the potential of AI in transforming the biotech industry.
4. **Potential AI Impact**: Gates has emphasized the importance of AI in addressing global health inequities, with a focus on improving education and healthcare outcomes. His investment in AI biotech aligns with this mission, aiming to create positive societal impact through technological innovation.

**AI Biotech Stocks with Potential**:
1. **BioNTech (BNTX)**: This company is a leader in mRNA-based therapies and has shown promising results in cancer vaccines and investigational antibody-drug conjugates.
2. **Vir Biotechnology (VIR)**: Vir is developing treatments for infectious diseases using monoclonal antibodies and has a prophylactic HIV vaccine in Phase 1 trials.
3. **Immunocore (IMCR)**: Immunocore is focused on T cell receptor (TCR)-based therapeutics for tuberculosis and HIV, with a significant stake from the Gates Foundation.

**Conclusion**: Bill Gates has been a prominent investor in AI biotech, particularly in companies like BioNTech, Vir Biotechnology, and Immunocore. These investments reflect his belief in the transformative potential of AI in healthcare and his commitment to addressing global health inequities.